|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MAP4K3 |
Gene summary for MAP4K3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MAP4K3 | Gene ID | 8491 |
| Gene name | mitogen-activated protein kinase kinase kinase kinase 3 | |
| Gene Alias | GLK | |
| Cytomap | 2p22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | B3KMM5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8491 | MAP4K3 | CCI_1 | Human | Cervix | CC | 2.33e-12 | 1.37e+00 | 0.528 |
| 8491 | MAP4K3 | CCI_2 | Human | Cervix | CC | 2.99e-12 | 1.07e+00 | 0.5249 |
| 8491 | MAP4K3 | CCI_3 | Human | Cervix | CC | 1.53e-14 | 7.80e-01 | 0.516 |
| 8491 | MAP4K3 | AEH-subject1 | Human | Endometrium | AEH | 1.29e-12 | 4.06e-01 | -0.3059 |
| 8491 | MAP4K3 | AEH-subject2 | Human | Endometrium | AEH | 5.01e-11 | 3.61e-01 | -0.2525 |
| 8491 | MAP4K3 | AEH-subject3 | Human | Endometrium | AEH | 2.47e-05 | 2.34e-01 | -0.2576 |
| 8491 | MAP4K3 | AEH-subject4 | Human | Endometrium | AEH | 4.91e-16 | 4.95e-01 | -0.2657 |
| 8491 | MAP4K3 | AEH-subject5 | Human | Endometrium | AEH | 2.27e-11 | 4.05e-01 | -0.2953 |
| 8491 | MAP4K3 | EEC-subject1 | Human | Endometrium | EEC | 1.63e-16 | 5.24e-01 | -0.2682 |
| 8491 | MAP4K3 | EEC-subject2 | Human | Endometrium | EEC | 4.95e-07 | 2.99e-01 | -0.2607 |
| 8491 | MAP4K3 | EEC-subject3 | Human | Endometrium | EEC | 2.53e-04 | 1.93e-01 | -0.2525 |
| 8491 | MAP4K3 | EEC-subject4 | Human | Endometrium | EEC | 3.72e-09 | 3.34e-01 | -0.2571 |
| 8491 | MAP4K3 | EEC-subject5 | Human | Endometrium | EEC | 6.43e-12 | 4.13e-01 | -0.249 |
| 8491 | MAP4K3 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 5.21e-07 | -6.40e-02 | -0.1869 |
| 8491 | MAP4K3 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 6.63e-09 | -6.95e-02 | -0.1875 |
| 8491 | MAP4K3 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 5.81e-09 | -5.08e-02 | -0.1883 |
| 8491 | MAP4K3 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 4.65e-07 | -3.18e-02 | -0.1934 |
| 8491 | MAP4K3 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 2.17e-10 | -8.70e-02 | -0.1917 |
| 8491 | MAP4K3 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 1.03e-07 | -5.57e-02 | -0.1916 |
| 8491 | MAP4K3 | LZE4T | Human | Esophagus | ESCC | 3.02e-06 | 1.44e-01 | 0.0811 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00310988 | Cervix | CC | stress-activated protein kinase signaling cascade | 58/2311 | 247/18723 | 8.02e-07 | 2.89e-05 | 58 |
| GO:00514038 | Cervix | CC | stress-activated MAPK cascade | 55/2311 | 239/18723 | 2.96e-06 | 8.31e-05 | 55 |
| GO:00346129 | Cervix | CC | response to tumor necrosis factor | 55/2311 | 253/18723 | 1.75e-05 | 3.32e-04 | 55 |
| GO:00093149 | Cervix | CC | response to radiation | 86/2311 | 456/18723 | 3.50e-05 | 5.63e-04 | 86 |
| GO:00094112 | Cervix | CC | response to UV | 33/2311 | 149/18723 | 5.51e-04 | 5.29e-03 | 33 |
| GO:00072545 | Cervix | CC | JNK cascade | 35/2311 | 167/18723 | 1.10e-03 | 9.09e-03 | 35 |
| GO:00094163 | Cervix | CC | response to light stimulus | 54/2311 | 320/18723 | 1.03e-02 | 4.97e-02 | 54 |
| GO:00514039 | Endometrium | AEH | stress-activated MAPK cascade | 50/2100 | 239/18723 | 9.33e-06 | 2.18e-04 | 50 |
| GO:00310989 | Endometrium | AEH | stress-activated protein kinase signaling cascade | 51/2100 | 247/18723 | 1.12e-05 | 2.52e-04 | 51 |
| GO:003461210 | Endometrium | AEH | response to tumor necrosis factor | 44/2100 | 253/18723 | 2.08e-03 | 1.61e-02 | 44 |
| GO:000931410 | Endometrium | AEH | response to radiation | 70/2100 | 456/18723 | 3.99e-03 | 2.68e-02 | 70 |
| GO:00072546 | Endometrium | AEH | JNK cascade | 30/2100 | 167/18723 | 6.16e-03 | 3.70e-02 | 30 |
| GO:005140314 | Endometrium | EEC | stress-activated MAPK cascade | 55/2168 | 239/18723 | 3.98e-07 | 1.56e-05 | 55 |
| GO:003109814 | Endometrium | EEC | stress-activated protein kinase signaling cascade | 56/2168 | 247/18723 | 5.25e-07 | 2.00e-05 | 56 |
| GO:003461215 | Endometrium | EEC | response to tumor necrosis factor | 48/2168 | 253/18723 | 3.77e-04 | 4.03e-03 | 48 |
| GO:000725414 | Endometrium | EEC | JNK cascade | 33/2168 | 167/18723 | 1.44e-03 | 1.17e-02 | 33 |
| GO:000931413 | Endometrium | EEC | response to radiation | 71/2168 | 456/18723 | 5.69e-03 | 3.42e-02 | 71 |
| GO:000941113 | Esophagus | ESCC | response to UV | 115/8552 | 149/18723 | 3.29e-15 | 1.93e-13 | 115 |
| GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
| GO:003109818 | Esophagus | ESCC | stress-activated protein kinase signaling cascade | 154/8552 | 247/18723 | 8.53e-08 | 1.44e-06 | 154 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
| hsa0401012 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
| hsa040108 | Lung | IAC | MAPK signaling pathway | 62/1053 | 302/8465 | 3.54e-05 | 6.38e-04 | 4.24e-04 | 62 |
| hsa0401011 | Lung | IAC | MAPK signaling pathway | 62/1053 | 302/8465 | 3.54e-05 | 6.38e-04 | 4.24e-04 | 62 |
| hsa0401021 | Lung | AIS | MAPK signaling pathway | 57/961 | 302/8465 | 6.41e-05 | 9.43e-04 | 6.03e-04 | 57 |
| hsa0401031 | Lung | AIS | MAPK signaling pathway | 57/961 | 302/8465 | 6.41e-05 | 9.43e-04 | 6.03e-04 | 57 |
| hsa0401010 | Prostate | BPH | MAPK signaling pathway | 87/1718 | 302/8465 | 2.05e-04 | 1.13e-03 | 6.98e-04 | 87 |
| hsa0401013 | Prostate | BPH | MAPK signaling pathway | 87/1718 | 302/8465 | 2.05e-04 | 1.13e-03 | 6.98e-04 | 87 |
| hsa0401022 | Prostate | Tumor | MAPK signaling pathway | 87/1791 | 302/8465 | 8.46e-04 | 3.94e-03 | 2.45e-03 | 87 |
| hsa0401032 | Prostate | Tumor | MAPK signaling pathway | 87/1791 | 302/8465 | 8.46e-04 | 3.94e-03 | 2.45e-03 | 87 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MAP4K3 | SNV | Missense_Mutation | c.1730T>G | p.Phe577Cys | p.F577C | Q8IVH8 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MAP4K3 | SNV | Missense_Mutation | rs764250055 | c.2258N>A | p.Arg753Gln | p.R753Q | Q8IVH8 | protein_coding | tolerated(0.53) | benign(0.027) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| MAP4K3 | SNV | Missense_Mutation | c.1294N>T | p.Pro432Ser | p.P432S | Q8IVH8 | protein_coding | tolerated(0.18) | benign(0.133) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| MAP4K3 | SNV | Missense_Mutation | c.832N>G | p.Thr278Ala | p.T278A | Q8IVH8 | protein_coding | tolerated(0.15) | benign(0.028) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| MAP4K3 | SNV | Missense_Mutation | rs778382212 | c.836N>A | p.Arg279Gln | p.R279Q | Q8IVH8 | protein_coding | tolerated(0.08) | benign(0.074) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MAP4K3 | SNV | Missense_Mutation | novel | c.716N>C | p.Lys239Thr | p.K239T | Q8IVH8 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| MAP4K3 | SNV | Missense_Mutation | c.872N>C | p.Asn291Thr | p.N291T | Q8IVH8 | protein_coding | deleterious(0) | probably_damaging(0.909) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MAP4K3 | SNV | Missense_Mutation | rs748398050 | c.982N>T | p.Arg328Cys | p.R328C | Q8IVH8 | protein_coding | tolerated(0.05) | possibly_damaging(0.586) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| MAP4K3 | SNV | Missense_Mutation | novel | c.1344N>A | p.Met448Ile | p.M448I | Q8IVH8 | protein_coding | tolerated(0.51) | benign(0) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MAP4K3 | SNV | Missense_Mutation | c.502C>T | p.Arg168Trp | p.R168W | Q8IVH8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B5-A0JV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 8491 | MAP4K3 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | inhibitor | 384403668 | ||
| 8491 | MAP4K3 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | inhibitor | 249565855 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |